
Initiate at Sell with a $298 target as peer valuation caps the recovery
We initiate on UnitedHealth Group at Sell (low conviction) with a $298 target (−12% total return). We price at the 18 Nov close of $349.91; at the 19 Nov close of $330.48 the return is −7%, inside our Hold band (p23). UNH runs UnitedHealthcare (UHC) and Optum’s care, IT and pharmacy units. Buyers pay 14.9x 2027 adjusted earnings per share (EPS), overpricing recovery in the medical care ratio (MCR, premiums spent on care).
- Peer multiple parity cuts $95 a share. Restating peers for UNH’s 13% growth and 22% return on equity (ROE) gives an 11.4x price-to-earnings (P/E) median vs 14.9x paid.
- Margins reach 6.3% in FY27E, 2.3pp below the historical median. The V28 risk-model phase-in and >11% commercial trend hold UHC margins near 4% vs 6.4% implied.
- Audit clawbacks cost $4 a share in base. Full Risk Adjustment Data Validation (RADV) recovery by the Centers for Medicare & Medicaid Services (CMS) under its proposed rule (CMS-6098-P, known as CRUSH) costs $12/sh vs a $62 drop.
What the market is missing. Our FY27E EPS is 1% above consensus; at 11.5x, $350 needs $31 EPS or a 6.4% UHC margin vs our 4.1%.
Catalysts. Dec investor update, 19 Jan CRUSH comments, 26 Jan Q4 results and the 2028 rate notices (late Jan, 6 Apr).
Valuation and target. Base value is $266 at 11.5x FY27E EPS less RADV; 25/50/25 bear/base/bull weights give $282, rolled to $298.
Risks. Unpriced trend (−$41/sh) and Department of Justice (DOJ) Medicare Advantage (MA) coding probes (−$24/sh) lead downside.
| Dec YE, US$bn | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Revenue | 400.3 | 447.6 | 449.8 | 464.8 | 487.2 |
| Growth y/y | +7.7% | +11.8% | +0.5% | +3.3% | +4.8% |
| Adj. op. earnings | 34.4 | 21.7 | 26.7 | 29.5 | 33.2 |
| Adj. op. margin | 8.6% | 4.9% | 5.9% | 6.3% | 6.8% |
| Adj. net income | 25.7 | 14.9 | 18.7 | 20.9 | 23.6 |
| Adj. EPS ($) | 27.66 | 16.35 | 20.73 | 23.52 | 27.35 |
| Growth y/y | +10.1% | −40.9% | +26.8% | +13.4% | +16.3% |
| FCF after SBC | 19.7 | 15.1 | 23.2 | 21.0 | 24.0 |
| At $349.91, 18 Nov | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| P/E (adjusted) | 12.7x | 21.4x | 16.9x | 14.9x | 12.8x |
| P/E (GAAP) | 22.6x | 26.4x | 17.8x | 15.7x | 13.4x |
| Price / book | 3.3x | 3.2x | 3.0x | 2.8x | 2.7x |
| FCF yield (after SBC) | 6.1% | 4.7% | 7.3% | 6.7% | 7.9% |
| Dividend yield | 2.3% | 2.5% | 2.6% | 2.7% | 2.9% |
| Adjusted ROE | 26.5% | 15.0% | 18.4% | 19.7% | 21.6% |
| Medical care ratio | 85.5% | 89.1% | 87.5% | n.a. | n.a. |
| P/E at $297.81 target | 10.8x | 18.2x | 14.4x | 12.7x | 10.9x |
Source: SEC filings; Yahoo Finance; Penmark model. P/B: avg. sh FY24A–25A, YE sh FY26E–28E. FCF = free cash flow; SBC = share-based compensation.
Our $266 base value and $298 target leave more downside than upside
Source: Yahoo Finance; Penmark Research valuation model. Spot values at 18 Nov 2026 rolled forward 12m at 5.46% (cost of equity less next-12m dividend yield).
FY27E adj. EPS $26.75 at 16.0x best-peer P/E; UHC margin 4.6%, Optum Health 5.0%, Medicare & Retirement (M&R) +7.0%; RADV vacated ($0).
FY27E adj. EPS $23.52 at 11.5x peer-median P/E less $4.08 RADV (35% upheld); UHC margin 4.1%, Optum Health 4.0%.
FY27E adj. EPS $17.18 at 10.5x lowest-peer P/E less $11.66 full RADV (100% upheld); UHC margin 3.0%, Optum Health 2.0%.
| Income stmt, $bn | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Revenue | 400.3 | 447.6 | 449.8 | 464.8 | 487.2 |
| Adj. EBITDA | 38.5 | 26.1 | 31.0 | 33.9 | 37.8 |
| Adj. op. earnings | 34.4 | 21.7 | 26.7 | 29.5 | 33.2 |
| GAAP op. earnings | 32.3 | 19.0 | 27.1 | 29.5 | 33.2 |
| Interest & sub. loss | (12.2) | (4.3) | (4.1) | (3.8) | (3.8) |
| Income tax & NCI | (5.7) | (2.6) | (5.3) | (5.8) | (6.7) |
| Net inc., adjusted | 25.7 | 14.9 | 18.7 | 20.9 | 23.6 |
| Net inc., GAAP | 14.4 | 12.1 | 17.7 | 19.8 | 22.6 |
| Cash flow, $bn | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Net inc., GAAP | 14.4 | 12.1 | 17.7 | 19.8 | 22.6 |
| D&A & working cap. | 9.8 | 7.6 | 10.1 | 5.1 | 5.5 |
| Operating cash flow | 24.2 | 19.7 | 27.8 | 24.9 | 28.1 |
| Capital expenditure | (3.5) | (3.6) | (3.8) | (4.0) | (4.1) |
| Less: reported SBC | (1.0) | (1.0) | (0.8) | 0.0 | 0.0 |
| FCF after SBC | 19.7 | 15.1 | 23.2 | 21.0 | 24.0 |
| Dividends paid | (7.5) | (7.9) | (8.3) | (8.5) | (8.8) |
| Share repurchases | (9.0) | (5.5) | (5.0) | (7.0) | (12.2) |
| Balance sheet, $bn | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Cash & investments | 81.5 | 82.4 | 85.9 | 88.3 | 91.3 |
| Receivables | 22.4 | 23.0 | 20.7 | 21.4 | 22.4 |
| Goodwill & PP&E | 160.1 | 164.7 | 169.4 | 169.0 | 168.5 |
| Total assets | 298.3 | 309.6 | 312.5 | 315.1 | 318.7 |
| Med. costs payable | 34.2 | 39.3 | 39.3 | 40.7 | 42.6 |
| Total debt | 76.9 | 78.4 | 74.3 | 71.3 | 71.3 |
| Cash & inv. less debt | 4.6 | 4.0 | 11.6 | 17.0 | 20.0 |
| Equity | 98.3 | 100.1 | 103.9 | 108.2 | 109.8 |
| Per share & KPIs | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Avg. diluted shares (m) | 929 | 911 | 904 | 888 | 863 |
| EPS, adjusted ($) | 27.66 | 16.35 | 20.73 | 23.52 | 27.35 |
| EPS, GAAP ($) | 15.51 | 13.23 | 19.62 | 22.34 | 26.20 |
| Dividend per share ($) | 8.11 | 8.69 | 9.13 | 9.51 | 9.99 |
| FCF after SBC / sh ($) | 21.19 | 16.58 | 25.67 | 23.61 | 27.80 |
| Book value / sh ($) | 105.78 | 109.87 | 115.71 | 123.24 | 129.54 |
| UHC margin | 5.4% | 2.8% | 3.7% | 4.1% | 4.4% |
| Optum Health margin | 7.5% | 2.2% | 3.0% | 4.0% | 5.0% |
Source: SEC 10-K and 8-K filings; Penmark Research model. EBITDA = earnings before interest, tax, depreciation and amortisation (D&A); NCI = noncontrolling interests; SBC = share-based compensation (deducted separately in FY24A–9M26A; forecast basis treats SBC as cash inside operating cash flow); book value per share uses average shares in FY24A–FY25A and year-end shares in FY26E–FY28E; model treats investments as backing reserves ($45.8bn net debt at 3Q26).
Adjusted ROE rebuilds to about 20% in FY27E; our EPS is 1% above consensus
| Growth, margins (%) | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Growth y/y | |||||
| Revenue | +7.7% | +11.8% | +0.5% | +3.3% | +4.8% |
| Adjusted EBITDA | +5.9% | −32.3% | +18.7% | +9.6% | +11.5% |
| Adj. op. earnings (EBIT) | +6.3% | −36.9% | +23.1% | +10.4% | +12.5% |
| Adjusted EPS | +10.1% | −40.9% | +26.8% | +13.4% | +16.3% |
| Dividend per share | +11.2% | +7.2% | +5.1% | +4.2% | +5.0% |
| Margins and coverage | |||||
| Medical care ratio (MCR) | 85.5% | 89.1% | 87.5% | n.a. | n.a. |
| Adj. EBITDA margin | 9.6% | 5.8% | 6.9% | 7.3% | 7.8% |
| Adj. operating margin | 8.6% | 4.9% | 5.9% | 6.3% | 6.8% |
| FCF after SBC margin | 4.9% | 3.4% | 5.2% | 4.5% | 4.9% |
| Adj. EBITDA / interest | 9.9x | 6.5x | 8.0x | 8.9x | 9.8x |
| Capex / revenue | 0.9% | 0.8% | 0.8% | 0.8% | 0.8% |
| Ratios and valuation | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Returns and capital structure | |||||
| Adjusted ROE (avg. eq.) | 26.5% | 15.0% | 18.4% | 19.7% | 21.6% |
| GAAP ROA (avg. assets) | 4.9% | 4.0% | 5.7% | 6.3% | 7.1% |
| Adj. ROCE (nopat / cap.) | 15.8% | 10.7% | 12.1% | 13.2% | 14.7% |
| Total debt / capital | 43.9% | 43.9% | 41.7% | 39.7% | 39.4% |
| Cash & inv. less debt ($bn) | +4.6 | +4.0 | +11.6 | +17.0 | +20.0 |
| Valuation at $349.91 current price | |||||
| P/E (adjusted) | 12.7x | 21.4x | 16.9x | 14.9x | 12.8x |
| P/E (GAAP) | 22.6x | 26.4x | 17.8x | 15.7x | 13.4x |
| Price / book | 3.3x | 3.2x | 3.0x | 2.8x | 2.7x |
| FCF yield (after SBC) | 6.1% | 4.7% | 7.3% | 6.7% | 7.9% |
| Dividend yield | 2.3% | 2.5% | 2.6% | 2.7% | 2.9% |
| P/E at $297.81 target | 10.8x | 18.2x | 14.4x | 12.7x | 10.9x |
Source: SEC filings; Penmark Research model. ROA = return on assets; ROCE = return on capital employed. Price / book uses average diluted shares in FY24A–FY25A and year-end shares in FY26E–FY28E. Our model treats investments as backing insurance reserves (net debt is $45.8bn at 3Q26 excluding regulated investments).
| US$m / US$ per share | 3Q26A | 4Q26E | FY26E | FY27E |
|---|---|---|---|---|
| Revenue ($m) | ||||
| Penmark / actual | 112,694 | 113,400 | 449,847 | 464,769 |
| Consensus | n.d. | 110,453 | 446,900 | Not found |
| Prior-year period | 113,161 | 113,215 | 447,567 | 449,847 |
| Diff. vs consensus | n.d. | +2.7% | +0.7% | n.d. |
| Growth y/y (Penmark) | −0.4% | +0.2% | +0.5% | +3.3% |
| Adjusted EPS ($) | ||||
| Penmark / actual | 4.69 | 2.39 | 20.73 | 23.52 |
| Consensus | n.d. | 2.29 | 20.59 | 23.29 |
| Prior-year period | 2.92 | 2.11 | 16.35 | 20.73 |
| Diff. vs consensus | n.d. | +4.3% | +0.7% | +1.0% |
| Growth y/y (Penmark) | +60.6% | +13.2% | +26.8% | +13.4% |
Source: Q3 FY26 8-K; clearank.com consensus (12 Nov 2026; 4Q26E implied by FY26E less 9M actual; FY27E revenue consensus not found).
Source: Company filings (A); clearank.com consensus; Penmark Research (E).
UNH trades at a 61% raw P/E premium to core managed-care peers despite similar growth
| FY27E, at 18 Nov price | UNH | Peers | Diff. |
|---|---|---|---|
| Valuation (company 2027 outlook basis) | |||
| P/E, FY27E raw (outlook) | 15.1x | 9.4x | +60.6% |
| P/E, restated for UNH g & ROE | 15.1x | 11.4x | +32.7% |
| Price / book (FY25A YE) | 3.4x | 1.8x | +84.2% |
| Forward dividend yield | 2.7% | 2.2% | +0.5pp |
| Growth, margins and returns | |||
| FY27E EPS growth (outlook) | 13.0% | 12.0% | +1.0pp |
| Forward ROE (FY27E / BV) | 22.4% | 15.3% | +7.1pp |
| Consolidated op. margin (9M26) | 6.9% | 4.0% | +2.9pp |
| UHC margin (9M26) | 4.8% | 4.0% | +0.8pp |
| Raw P/E, all 6 peers median | 15.1x | 13.2x | +14.6% |
| Restated P/E incl. CNC | 15.1x | 13.6x | +10.8% |
Source: Company outlooks; Penmark Research model (ELV, CI, CVS core; FY25A P/B 3.4x on YE BVPS $103.30 vs 3.2x avg. sh in Ex. 1 & 9; peer margin med. 4.0%: ELV 4.6%, CI 4.0%, HUM 3.5%); Yahoo Finance.
- Dec 2026Investor update sets FY27 EPS framework (≥$23.17 floor).
- 19 Jan 27CRUSH comments close on payment year (PY) 2018–27 RADV.
- 26 Jan 27Q4 results & FY27 guide; our $23.52 vs $23.29 Street.
- Late Jan2028 MA Advance Notice sets draft rates & coding rules.
- 6 Apr 272028 MA Final Notice sets rates before June bids; Q1 MCR mid-April.
Source: CMS docket CMS-6098-P; company calendar; Penmark Research.
- Trend outruns pricing. UHC margin falls to 3.0%. 20% prob.; −$40.78/sh.
- DOJ MA coding probe. Settlement cuts P/E to 10.5x. 20% prob.; −$23.52/sh.
- CRUSH RADV upheld. Full 10-yr rule adds $7.58/sh. 35% prob.; −$7.58/sh.
- Bull recovery. $26.75 EPS at 16.0x, $0 RADV. 25% bull; +$161.71/sh.
Source: Penmark Research model.
Source: Yahoo Finance; company filings; Penmark Research (15.0x on consensus FY27E EPS). Standard deviation (SD) bands around 5-year monthly mean.
Source: Signals; Yahoo Finance; Penmark Research (FY25A year-end BVPS $103.30; 18 Nov 2026). Ordinary least squares (OLS) fit across 6 US managed-care peers ex-UNH (R² = 0.16).
MCR swings drove the derating, and peer multiple parity leaves 24% downside to base value
Source: Company 8-K releases; Yahoo Finance; Penmark model (2Q26 MCR n.a. in model). Quarterly correlation r = −0.26 (seven plotted quarters with MCR, 4Q24–3Q26).
Source: Penmark Research valuation model.
Source: Company filings (A); Penmark Research model (E).
Source: Company filings (A); Penmark Research model (E).
Source: Yahoo Finance; company filings (3.0x on 3Q26 reported equity of $104.1bn / 902m diluted sh). Bands show ±1 and ±2 SD around 5-year mean.
Source: Yahoo Finance; company filings; Penmark Research (price and dividend returns to 18 Nov 2026).
Three debates separate our $266 value from the $350 price; the P/E debate dominates
| Debate | Market view | Penmark view | Evidence | What changes our view | Resolves |
|---|---|---|---|---|---|
| Peer multiple gap (−$94.65/sh) | Integrated compounder worth 14.9x FY27E EPS, or 15.5x with RADV added back. | 11.5x restated peer median (ELV, CI, CVS) captures federal policy risk. | 9M26 UHC margin (4.8%) sits near ELV (4.6%); DOJ MA coding probe and V28 cap re-rating. | Our base multiple above 12.1x (Hold). We also watch for a DOJ coding resolution. | Apr 2027 |
| Margin normalisation (+$3.52/sh on FY27E EPS) | Consensus $23.29 FY27E EPS; price implies 6.4% UHC margin at 11.5x. | $23.52 FY27E EPS; consolidated margin reaches 7.5% in FY30E (~7.7% from FY31E) vs 8.65% median. | Commercial trend >11%, 100% pharmacy benefit manager (PBM) rebate pass-through by 2028, Optum Health value-based care (VBC) rebuild. | FY27E EPS guided above $24.80 (Hold) or the 8.65% historical median margin (Buy). We also watch MCR below 86.5%. | Jan–Jul 27 |
| RADV clawback rule (+$7.58/sh vs 100% priced) | Two-day $62.11/sh drop priced full CRUSH RADV extrapolation plus policy contagion. | 35% probability upheld = $4.08/sh expected PV ($11.66/sh at 100% upheld). | CMS $9bn/yr industry estimate × 21.1% UNH reported MA enrolment share (vs 26% KFF all-MA share) over 10 yrs; 5th Circuit appeal. | CMS withdraws PY2018–PY2027 extrapolation (bull +$4.08/sh) or wins full enforcement. | Jan / 2H27 |
Source: Penmark Research model. Sequential bridge from $349.91 price to $266.36 base value (−$83.55/sh net). 15.5x = ($349.91 + $12 RADV) / consensus FY27E EPS.
Source: Penmark Research model (13.0% is the discounted cash flow (DCF) discount rate at base P/E value vs 8.2% capital asset pricing model (CAPM) cost of equity).
How the debates map to our thesis
Our Sell call rests on valuation discipline rather than an earnings miss. Our FY27E adjusted EPS sits 1% above consensus, adding about $4 a share.
Our 35% RADV weight adds $8 a share vs full enforcement. Repricing to 11.5x from 15.5x (consensus EPS, full $12 RADV cost added back) deducts $95 a share.
Source: CMS docket CMS-6098-P; company calendar; Penmark Research.
UnitedHealthcare is Optum’s biggest customer, worth $168bn a year
UnitedHealth Group serves 48 million medical members and treats patients, dispenses drugs and routes claims across Optum. Its engine is an internal bridge where insurer spending feeds its own clinics and pharmacies. Federal auditors now scrutinise that bridge.
Every morning across the US, a senior in a UnitedHealthcare Medicare Advantage plan visits an Optum clinic and fills a prescription. No cash changes hands at the desk, yet three ledgers move at once. The insurer collects a monthly federal premium, pays its clinic a capitated budget and routes the drug claim through Optum Rx, its own PBM.
How the money comes in
Monthly premiums arrive up front, funding $87bn of cash and investments before claims settle. In FY25A, UnitedHealthcare generated $345bn and Optum $271bn; cancelling $168bn of internal billings left $448bn of consolidated revenue. At the FY25A trough, claims and costs took 95.1 cents per dollar, leaving $22bn of operating profit and $15bn of free cash flow.
Where the story turns
After unifying Optum in 2011 and buying Change Healthcare for $14bn in October 2022, vertical integration looked durable. In 2025, the V28 risk-model phase-in met rising outpatient and drug bills, lifting the MCR to 89.1% and cutting adjusted EPS by 41% to $16. Stephen Hemsley returned as CEO in May 2025. UNH has shed 1.3m commercial risk lives since December 2024 and repriced 2026 plans.
Why it works, and what could break it
Switching networks disrupts doctors and drug lists, supporting a 22% forward ROE. Yet the bridge between insurer and clinic faces the RADV clawback rule, DOJ MA coding probes and commercial trend above 11%, driving margin normalisation and the peer multiple gap.
Source: SEC FY25 10-K and Q3 FY26 8-K; Penmark Research model. Tie to the stock: investors pay 14.9x for this platform (15.1x on the 2027 floor) vs a 9.4x raw core-peer median.
Vertical integration links $345bn of health plans to $271bn of Optum care and pharmacy
Source: SEC FY25 10-K and 2026 DEF 14A; Reuters; Penmark Research model.
1 · Customers
CMS (Medicare)8.45m MA lives FY25A; $171.3bn M&R rev. States (Medicaid)
7.38m Community & State (C&S) lives; $94.4bn rev. Employers & Ind.
8.17m risk + ASO fees; $79.2bn rev. External payers/prov.
$102.7bn external Optum sales.
2 · Offerings
UHC BenefitsRisk & fee medical plans ($344.9bn). Optum Rx (PBM)
Formulary, mail & specialty ($154.7bn). Optum Health
Capitated & FFS clinics ($102.0bn). Optum Insight
Claims IT & analytics ($19.4bn).
3 · Revenue mix
Premiums (78.7%)$352.2bn underwriting risk. Products (12.1%)
$54.1bn pharmacy dispensing. Services (8.2%)
$36.5bn ASO, IT & clinic fees. Investment inc. (1.1%)
$4.7bn yield on $82.4bn cash & inv.
4 · Segment footing
UHC gross rev.$344.9bn medical benefit plans. Optum net rev.
$270.6bn (net of $5.5bn intra-Optum). Corp. eliminations
−$168.0bn UHC-to-Optum billings. Consolidated net
$447.6bn external revenue.
5 · Cost to serve
Medical care$314.0bn claims (89.1% MCR). Operating & drugs
$107.5bn clinic, PBM & admin. D&A & interest
$4.4bn D&A + $4.0bn interest. Low capex
$3.6bn (0.8% of revenue).
6 · What is left
Adj. op. profit$21.7bn FY25A (4.9% margin). FY27E rebuild
$29.5bn (6.3% margin). FCF after SBC
$15.1bn FY25A; $21.0bn FY27E. Cash returned
$13.5bn div + buybacks FY25A.
Source: SEC FY25 10-K, Q4 FY25 8-K and Q3 FY26 8-K; Penmark model. ASO = administrative services only; FFS = fee-for-service.
Pricing is set annually ahead of medical claims, making underwriting accuracy the main profit swing. CMS fixes MA benchmark rates each April while employers renew in Q4. Medical costs are over 85% variable, leaving little cushion when utilisation spikes.
Working capital runs negative, turning profit quickly into cash despite subsidiary lock-up. Premiums arrive monthly while $39bn of claims payable sit 45 to 50 days on the balance sheet, funding $87bn of cash and investments, though statutory rules retain about $2.4bn a year inside insurance entities.
Medicare & Retirement drives 38% of revenue, while Optum generates half of operating profit
Source: Company 9M FY26 8-K; Penmark Research FY26E model.
Source: Company FY25 10-K and Q4 FY25 8-K; Penmark Research.
Source: Penmark Research valuation model.
| Segment / concentration ($bn) | FY25A | FY27E | Share | Margin |
|---|---|---|---|---|
| Segment breakdown (FY27E margin shown) | ||||
| UHC Medicare & Retirement | 171.3 | 177.8 | 38.2% | 4.1%* |
| UHC Community & State | 94.4 | 96.1 | 20.7% | 4.1%* |
| UHC Employer & Individual | 79.2 | 82.9 | 17.8% | 4.1%* |
| Optum Rx (gross PBM) | 154.7 | 161.5 | 34.7% | 3.85% |
| Optum Health (clinics/VBC) | 102.0 | 95.4 | 20.5% | 4.0% |
| Optum Insight (IT/claims) | 19.4 | 22.5 | 4.8% | 21.5% |
| Less: Optum & corp. elim. | (173.4) | (171.3) | −36.9% | n.m. |
| Geographic & payer concentration | ||||
| US domestic share (ex-S. America) | >98% | >99% | US focus | n.m. |
| CMS + state Medicaid exposure | 265.7 | 273.8 | 58.9% | Policy |
Source: SEC FY25 10-K; Penmark Research model. *UHC margin is reported at total segment level (4.1% FY27E). FY25A Optum Health and Insight are pre-recast.
Government programmes fund 39% of $5.3tn US health spend, putting CMS at the centre of margins
Source: CMS National Health Expenditure Fact Sheet (2024).
Market size and cycle position
US National Health Expenditure (NHE) reached $5.3tn (18% of gross domestic product, GDP) in 2024, growing 5% to 6% a year. Private insurance ($1.65tn), federal Medicare ($1.12tn) and Medicaid ($932bn) pay for $3.7tn of pooled benefits.
Medicare Advantage covers 35m seniors, or 55% of eligible beneficiaries. Growth sits in dual-eligible special-needs plans (D-SNP) and chronic-condition special-needs plans (C-SNP). KFF puts UNH at 26% of all MA members in 2026 (including group and SNP), whereas our RADV model uses UNH’s 7.6m reported MA members (21.1% of ~36m).
The cycle is leaving its 2024–25 trough. The V28 risk-model phase-in, Medicaid redeterminations and commercial hospital and drug inflation above 11% compressed margins and forced 2026–27 plan repricing.
Source: CMS; company FY25 10-K; Drug Channels Institute; Penmark Research.
Source: KFF Medicare Advantage 2026 Enrollment Update (March 2026; all-MA incl. group/SNP).
Source: Company Q4 FY25 and Q3 FY26 8-K releases.
Scale and Optum integration lift ROE to 22%, while 9M26 UHC margin sits at 4.8%
Source: Company filings; KFF; Drug Channels; Penmark Research.
Source: Company 9M FY26 8-K; Penmark Research model (latest reported: ELV 4.6%, CI 4.0%, HUM 3.5%).
| Segment & peers | Customer choice criteria | UNH rank | Source of advantage & durability | Share & retention trend |
|---|---|---|---|---|
| Medicare Advantage HUM, CVS, ELV |
Zero-premium benefits, doctor network, Star ratings (≥4 stars). | #1 (26% share) | Local network density + Optum capitated clinics; ≥69% of members in 4+ Star plans for 2028. | KFF all-MA share eased from 29% (2025) to 26% (2026) on plan exits; HUM rose to 20%. |
| Employer & Individual (E&I) ELV, CI, CVS |
Provider discounts, stop-loss, bundled ASO + PBM + specialty tools. | #1 national | National provider discount book and integrated Optum Insight and Rx analytics lower employer trend. | Risk lives pruned 14% from Dec 2024 to Sep 2026 (8.85m to 7.58m) to defend margin. |
| Medicaid (C&S) CNC, MOH, ELV |
State bid quality scores, D-SNP integration, behavioural care. | Top 3 (6.70m) | Multi-state contract record and D-SNP care management cross-sell into Medicare Advantage. | Acuity mismatch after redeterminations pushed 2026 core margin near −1%; state rates lag. |
| PBM (Optum Rx) CI (ESI), CVS |
Net drug cost, specialty pharmacy access, rebate transparency. | #3 (23% Rx) | Top-3 oligopoly (ESI 31%, CVS 26%, UNH 23% = 80% of US scripts); captive UHC volume anchors scale. | 3Q26 scripts 393m vs 414m y/y; moving to 100% rebate pass-through by Jan 2028 (3.8% margin). |
| Care & Claims IT CVS/Oak St, Waystar |
Capitated risk capability, real-time electronic claims network. | #1 clinics & IT | 92m Optum Health consumers (3Q26) and Change Healthcare rails create high switching costs. | Optum Health Q3 rev −10% y/y on VBC contract exits; Insight 9M26 margin reached 21.3%. |
Source: SEC FY25 10-K and Q3 FY26 8-K; KFF (Mar 2026); Drug Channels Institute (2025); Penmark Research.
Why the moat earns 22% ROE without justifying 15x P/E. Capital-light PBM and software earnings lift group ROE 7pp above the 15% peer median, and our peer restatement formula already credits UNH’s 22% ROE in reaching 11.5x.
Scale has shifted from a pure cost edge into an audit magnet. Leading MA at 26% while owning Change Healthcare and 92m-consumer Optum Health leaves UNH exposed to federal RADV audits and DOJ MA coding probes.
Top five leaders hold $531m of shares and near-term awards, with 79%–99% equity pay
| Who | Tenure & background | How they are paid (FY25A) | What they own (at $349.91) |
|---|---|---|---|
| Stephen HemsleyCEO & Chair of the Board | Returned May 202529 yrs at UNH (CEO 2006–17; Chair since 2017; Arthur Andersen). | $60.94m total $0.94m salary/other; $60.00m options (3-yr vest + 2-yr hold). |
$467.39m (1,335,742 sh)0.15% of shares; 784x FY25 paid salary (10x req.); 0 Form 4 sales. |
| Wayne DeVeydtChief Financial Officer | Started Sep 2025 (New)<2 yrs at UNH; ex-Bain Capital, Surgery Partners CEO, Anthem CFO. | $14.58m total $2.70m cash/sign-on; $11.50m equity (50% PSUs: EPS & ROE). |
$6.88m (19,667 sh)<0.01% of shares; 2 Sep 26 Form 4 tax settlement (−1,209 sh at $399.66). |
| Timothy NoelCEO, UnitedHealthcare | Role Jan 202519 yrs at UNH (joined 2007; ran Medicare & Retirement). | $20.20m total $1.75m cash bonus; $17.00m equity (50% PSUs, 25% opt, 25% RSUs). |
$14.94m (42,683 sh*)<0.01%; 15.2x salary; 11 Nov 26 tax settlement (−587 sh at $402.94). |
| Patrick Conway, M.D.CEO, Optum | Role May 2025Joined UNH 2020; ex-Optum Rx CEO, Blue Cross NC CEO, CMS. | $19.92m total $1.75m cash bonus; $17.00m equity (3-yr cum. adj. EPS & avg. ROE). |
$26.87m (76,797 sh*)<0.01%; 27.4x salary; Aug 26 open-market sales (−1,669 sh, $661k). |
| Christopher ZaettaEVP & Chief Legal Officer | Role May 2024Leads RADV litigation & DOJ defence; Corporate Secretary. | $15.79m total $0.93m cash bonus; $14.00m equity (50% PSUs: EPS & ROE). |
$14.99m (42,829 sh*)<0.01%; 17.7x salary; no Aug–Nov 2026 open-market sales. |
Source: 2026 DEF 14A Proxy Statement (FY25 pay; holdings as of 2 Apr 2026 valued at $349.91); SEC Form 4 filings. EVP = Executive Vice President; PSU = performance stock unit; RSU = restricted stock unit.
Source: SEC Form 4 filings via Signals (Aug–Nov 2026).
Incentive alignment and board governance
Long-term incentives reward per-share earnings and ROE, though option-heavy CEO pay favours upside volatility. Segment chiefs receive half of annual equity in PSUs split equally between three-year cumulative adjusted EPS and average ROE, alongside options and RSUs.
Investor feedback in 2025 prompted governance changes, though Chair and CEO roles stay combined. The board raised CEO ownership rules to 10x salary, added a two-year post-vesting hold on Hemsley’s option grant and has a Lead Independent Director. Officers and directors hold 0.19% of shares under one-share-one-vote rules.
Management pivoted from $18bn of FY24–25 M&A to deleveraging toward 40% debt-to-capital
Source: Company FY25 10-K and Q3 FY26 8-K (FY24A–9M FY26A).
Source: Company filings (A); Penmark Research model (E).
Source: Company earnings releases; Penmark Research model.
| Use of cash | FY24A–9M26A spend | Forecast policy | Return vs 8.2% CAPM / 10.7% implied CoE | Assessment |
|---|---|---|---|---|
| Dividends | $21.62bn (31% CFO) | $8.5bn FY27E (+5%/yr) | 2.7% next-12m yield; absorbs ~55% of FY27E free cash flow to equity (FCFE, $15.55bn) while cutting leverage. | Disciplined |
| Share repurchases | $19.58bn (28% CFO) | Surplus FCFE ($7.0bn FY27E) | At 14.9x FY27E P/E, retiring shares above our $282 weighted value transfers value to selling holders. | Dilutive >$282 |
| Acquisitions (M&A) | $19.46bn net cash | $0 modelled; debt <40% | Built Optum scale (>$100bn goodwill), though South American exits caused an $8.3bn FY24A loss. | Paused |
| Organic capex | $9.54bn (0.8% rev) | $3.95bn FY27E (0.85%) | Funds software, claims automation and clinics (our DCF assumes an 18% terminal return on new equity). | Essential |
Source: SEC 10-K and 8-K filings; Penmark Research model. CAPM = capital asset pricing model; CoE = cost of equity.
UNH trades on MCR surprises, CMS policy rules and Optum Health margins, not market beta
We tested seven candidate drivers across ten company and policy events, multi-year total returns, three-year weekly regressions and 75 analyst questions on the last eight calls. Three drivers pass at least three of four tests; market beta explains just 1% of variance.
| Confirmed driver | What moves the stock | Tests confirmed | Market vs Penmark value | Linked debate | Next number to watch |
|---|---|---|---|---|---|
| MCR & medical cost trend | Quarterly MCR vs guide; 100bp on $356.7bn FY27E UHC rev = ~$3.6bn (vs $14.6bn UHC profit). | Four of four tests | 1Q25 miss cut −22.5pp; ±50bp UHC margin = ±$18.27/sh in model. | Margin normalisation | 4Q26 MCR (26 Jan 27): Penmark 91.0% seasonal, FY26E 87.5% vs 88.3%–89.3% initial guide. |
| CMS MA rates & RADV rule | V28 coding phase-in, April MA rate notices and CMS-6098-P CRUSH audit rule. | Three of four tests | CRUSH rule cut −$62.11/sh (−15.1%); base expected PV is −$4.08/sh ($58/sh gap). | Peer multiple gap & RADV clawback | CRUSH comments close 19 Jan 27; the 2028 Advance Notice arrives in late January 2027. |
| Optum Health VBC margins | Capitated clinic operating margin vs management’s 6%–8% 2028 target. | Three of four tests | 4Q25/FY26 guide reset cut −20.0pp; ±50bp Optum Health (OH) margin = ±$4.88/sh in base. | Margin normalisation | 4Q26 Optum Health margin (26 Jan 27): Penmark −1.1% seasonal, FY26E 3.0%, FY27E 4.0%. |
Source: Signals transcripts and KPIs; Yahoo Finance; Penmark Research model.
Source: Yahoo Finance; SEC 8-K releases (8 largest moves, 4Q24–Nov 2026).
Source: Yahoo Finance; Penmark Research valuation model.
Company news explains 86% of variance, and three topics take 81% of analyst Q&A
Source: Yahoo Finance 3-year weekly regression to 18 Nov 2026 (R² = 0.14).
Source: Signals transcripts (4Q24–3Q26, n = 75 questions); Penmark coding.
MCR & medical cost trend: Every 50bp UHC margin shift moves base value by $18 a share (±7%)
Market reaction vs model: MCR took 51% of call Q&A (38 of 75 questions; management tone turned hedged in 1H25 before firming in 2Q–3Q26) and drove a 23pp excess drop on 1Q25 results. The share price implies a 6.4% FY27E UHC margin at 11.5x against our 4.1% ($84/sh gap); watch 4Q26 MCR on 26 Jan 2027 (Penmark 91.0%; above 92% risks a 5%–8% drop).
CMS MA rates & RADV policy: Policy risk cuts peer P/E by $95/sh while base RADV cost is $4/sh
Market reaction vs model: Policy took 15% of Q&A (11 questions) and drove a $62/sh (15%) drop on 17–18 Nov 2026 when CMS proposed CRUSH. That exceeded our base RADV cost by $58 a share, or 93% of the drop, yet left UNH at 14.9x vs 11.5x; watch 19 Jan 2027 comments and the 2028 Advance Notice in late January 2027.
Optum Health VBC margin rebuild: Clinic repricing lags management’s 2028 target by 100bp in base
Market reaction vs model: Optum Health took 16% of Q&A (12 questions, hedged on multi-year V28 clinic lag) and contributed to the 20pp drop on 27 Jan 2026. A 50bp Optum Health margin shift moves base value by about $5 a share (±2%), linking to margin normalisation; watch FY27 segment guidance on 26 Jan 2027 (Penmark 4.0%).
| Candidate tested & dropped | Tests passed | Empirical evidence from 2024–2026 sample | Why dropped |
|---|---|---|---|
| Broad equity market (S&P 500) | Zero of four | 3Y weekly OLS R² = 0.01 (5Y monthly raw beta = 0.60); 0% of Q&A. | Policy and MCR swamp macro beta. |
| Interest rates / float yield | Zero of four | Investment income is 1.1% of FY25A revenue ($4.7bn); 0 of 75 call questions. | Underwriting spread dwarfs yield. |
| Commercial membership & ASO mix | One of four | 9.3% of Q&A (7 questions), but capital-light ASO fees carry minimal MCR volatility. | Risk MCR drives profit variance. |
| Quarterly buyback pace | One of four | 2.7% of Q&A (2 questions); our model assumes zero Q4 FY26 buybacks during debt paydown. | Deleveraging is well telegraphed. |
Source: Yahoo Finance weekly returns (Nov 2023–Nov 2026, n = 156 weeks); Signals transcripts (4Q24–3Q26, n = 75 questions; topic coding is Penmark analysis). Limits: multi-factor event days bundle drivers.
What the market believes
Bulls treat UNH’s 18.5x five-year average forward P/E as its normal level. At $350, investors pay 14.9x our FY27E EPS (15.1x on the company’s 2027 floor, or 15.5x with RADV added back), assuming integration insulates UNH from the 8.6x to 13.4x multiples paid for peers.
The evidence (three independent sources)
- Peer 2027 outlooks & ROE formula: Adjusting Elevance (13.4x), Cigna (8.6x) and CVS (9.4x) for UNH’s 13% growth and 22% forward ROE gives 15.9x, 11.4x and 10.4x, a median of 11.4x (11.5x base rule).
- Segment filings: UHC’s 9M26 margin is 4.8% (3.7% in FY26E) against a 4.0% peer median (ELV 4.6%, CI 4.0%, HUM 3.5%), while $118bn of 9M26 internal billings rules out a sum-of-the-parts valuation.
- DOJ & DCF cross-check: Our base P/E value equates to a 13% DCF discount rate against 8.2% CAPM, pricing DOJ MA coding probes and MA rate risk.
Source: Signals; company Q3 2026 calls; Penmark Research model (company-outlook basis).
Source: Penmark Research DCF discount-rate reconciliation.
| Company (18 Nov price) | Price ($) | FY27E EPS ($) | Raw P/E | FY27E g | FY25 BV ($) | Fwd ROE | Restated P/E | Model role |
|---|---|---|---|---|---|---|---|---|
| Elevance Health (ELV) | 401.07 | 29.96 | 13.4x | 12.0% | 195.38 | 15.3% | 15.9x | Bull rule (16.0x) |
| Cigna Group (CI) | 285.30 | 33.00 | 8.6x | 10.0% | 155.32 | 21.2% | 11.4x | Base median (11.5x) |
| CVS Health (CVS) | 81.34 | 8.65 | 9.4x | 13.1% | 59.18 | 14.6% | 10.4x | Bear rule (10.5x) |
| Centene (CNC, sens.) | 67.45 | 5.20 | 13.0x | 10.6%* | 40.46 | 12.9% | 18.4x | Excl.: no 2027 guide |
| Humana / Molina (avg.) | n.m. | n.m. | 21.2x | 87.2% | n.m. | n.m. | n.m. | Excl.: trough rebound |
| UnitedHealth (UNH) | 349.91 | 23.17 | 15.1x | 13.0% | 103.30 | 22.4% | 11.5x | Target multiple |
Source: Company post-3Q26 outlooks; Penmark Research model (g = 3.5% terminal growth in restatement formula; UNH FY27E P/E is 14.9x on Penmark $23.52 EPS and 15.1x on the $23.17 outlook floor). *CNC guides formally in Feb 2027.
What it is worth
Moving to 11.5x from 15.5x (RADV added back) cuts $95 a share (27% of the share price). A further 1.0x DOJ MA coding derating to 10.5x in bear costs $24 a share.
Signposts & what changes our view
Watch the 6 Apr 2027 MA Final Notice and DOJ filings. Our base multiple rising above 12.1x would move our rating to Hold on its own. We also watch for a clean DOJ coding settlement.
What the market believes
Consensus FY27E EPS sits 1% below us, yet the $350 price implies an 8.1% group margin or 6.4% UHC margin at 11.5x. Bulls treat FY25A’s 4.9% margin as brief before returning to the 8.65% FY20A–FY25A median.
The evidence (three independent sources)
- 9M26 8-K progression: 3Q26 MCR eased to 88.4% (9M26 86.3% vs 89.1% FY25A); Optum Health earned 4.4% in 9M26 ($3.1bn on $70.5bn revenue).
- 3Q26 call disclosures: Commercial trend above 11% slows employer recovery, core Medicaid sits near −1%, and Optum Health’s 6%–8% goal takes years.
- PBM & V28 rules: Client shifts to 100% rebate pass-through hold Optum Rx at 3.80% from FY28E, and the V28 risk-model phase-in curbs coding lifts.
| Adjusted op. margin | FY24A | FY25A | FY27E | FY30E | Implied / Target |
|---|---|---|---|---|---|
| UnitedHealthcare | 5.4% | 2.8% | 4.1% | 4.9% | 6.4% at $349.91 |
| Optum Health | 7.5% | 2.2% | 4.0% | 6.25% | 6–8% mgmt 28* |
| Optum Insight | 23.4% | 19.2% | 21.5% | 22.0% | ~22% steady |
| Optum Rx | 4.4% | 4.0% | 3.85% | 3.80% | Rebate pass-thru |
| Consolidated UNH | 8.6% | 4.9% | 6.3% | 7.5% | 8.65% FY20–25 med. |
| Value per share impact at 11.5x base P/E | |||||
| Base FY27E (6.35%) | EPS $23.52 less $4.08 RADV | $266.36 | Sell (−23.9%) | ||
| Norm. FY30E (7.52%) | Applied to FY27E revenue | $321.19 | Below $349.91 | ||
| Hist. median (8.65%) | Robustness test (Buy flip) | $374.06 | +15.5% 12m TR | ||
Source: Company filings; Penmark Research model (~7.7% margin from FY31E). *Mgmt targets 6%–8% by 2028; we model 5.0% FY28E and 6.25% FY30E (6.0% bull). TR = total return.
Source: Company filings (A); Penmark Research model (E).
What it is worth
The 2.3pp gap between our 6.35% FY27E margin and the 8.65% historical median is worth $108 a share ($266 vs $374). In bear, unpriced medical trend returning UHC’s margin to 3.0% cuts $41 a share.
Signposts & what changes our view
Watch 26 Jan 2027 segment guidance and April’s 1Q27 MCR. Sub-86.5% MCR and Optum Health reaching a 6% operating margin in FY27E–FY28E would support our $428 bull case.
What the market believes
When CMS released the CRUSH proposed rule (CMS-6098-P), UNH fell from $412 on 16 Nov to $350 on 18 Nov (−$62 a share, or −$56bn across 902m diluted shares). Traders priced full 10-year audit clawbacks plus lasting MA margin damage.
The evidence (three independent sources)
- CMS-6098-P fiscal math: CMS estimates $9bn per payment year of extrapolated RADV recoveries across PY2018–PY2027 (10 years). At UNH’s 21.1% reported MA enrolment share (vs 26% KFF all-MA share), after-tax 10-year PV is $10.5bn, or $12 a share.
- 5th Circuit appeal: CMS’s 2023 RADV rule was vacated in N.D. Texas in Sep 2025 and the appeal has been heard in the 5th Circuit; Administrative Procedure Act (APA) challenges push recoupment to late 2027 or beyond.
- Rate-notice offset: Separate MA rate-notice proposals to exclude unlinked chart reviews in 2028 cost under $2 a share in bear because insurers reprice annual bids.
Source: CMS-6098-P fact sheet; Yahoo Finance; Penmark Research model.
| RADV liability build & scenarios | Basis / weight | Total ($m) | Per share ($) | Gap vs $349.91 |
|---|---|---|---|---|
| CMS industry RADV recovery (10 yrs) | $9bn / yr × 10 (PY2018–PY2027) | 90,000 | n.m. | CMS-6098-P est. |
| UNH MA enrolment share (gross) | 21.1% MA enrolment share | 18,990 | $21.05 | Pre-tax, undiscounted |
| After-tax 10-yr PV (100% upheld) | Bear (100%) | (10,517) | ($11.66) | −$7.58/sh vs base |
| Penmark base expected RADV PV | Base (35%) | (3,681) | ($4.08) | +$7.58/sh vs 100% |
| Extrapolation vacated / withdrawn | Bull (0%) | 0 | $0.00 | +$4.08/sh vs base |
| Two-day UNH drop (17–18 Nov 26) | 902m sh × −$62.11 | (56,023) | ($62.11) | 15.2x base PV |
Source: CMS-6098-P; Yahoo Finance; Penmark Research model (21.1% = 7.6m reported UNH MA members / ~36m total members).
What it is worth (counter-evidence to our Sell)
The November CRUSH sell-off exceeded our expected RADV cash cost by $58 a share. Adding back $8 a share relative to full RADV enforcement still leaves UNH overvalued by $84 a share on peer P/E.
Signposts & what changes our view
Public comments close 19 Jan 2027; the 5th Circuit ruling and final rule follow in 2027. Vacating RADV adds $4 a share directly and could lift peer multiples if paired with supportive 2028 MA rates.
Revenue compounded at about 12% over five years, until FY25A MCR ended an 8%–9% margin run
| US$bn / per share | FY20A | FY21A | FY22A | FY23A | FY24A | FY25A | 9M25A | 9M26A |
|---|---|---|---|---|---|---|---|---|
| Revenue ($bn) | 257.1 | 287.6 | 324.2 | 371.6 | 400.3 | 447.6 | 334.4 | 336.4 |
| Revenue growth y/y | n.d. | +11.8% | +12.7% | +14.6% | +7.7% | +11.8% | n.m. | +0.6% |
| GAAP op. earnings ($bn) | 22.4 | 24.0 | 28.4 | 32.4 | 32.3 | 19.0 | 18.6 | 23.5 |
| GAAP op. margin | 8.7% | 8.3% | 8.8% | 8.7% | 8.1% | 4.2% | 5.6% | 7.0% |
| Adj. op. earnings ($bn) | n.d. | n.d. | n.d. | n.d. | 34.4 | 21.7 | 18.6 | 23.2 |
| UHC margin | 6.2% | 5.4% | 5.8% | 5.8% | 5.4% | 2.8% | 3.5% | 4.8% |
| Medical care ratio | n.d. | n.d. | n.d. | n.d. | 85.5% | 89.1% | 88.1% | 86.3% |
| Adjusted EPS ($) | n.d. | 19.02 | 22.19 | 25.12 | 27.66 | 16.35 | 14.22 | 18.30 |
| GAAP diluted EPS ($) | 16.03 | 18.08 | 21.18 | 23.86 | 15.51 | 13.23 | 13.21 | 17.50 |
| FCF-after-SBC / adj. NI | n.d. | n.d. | n.d. | n.d. | 76.6% | 101.4% | n.m. | 131.5% |
Source: SEC 10-K and 8-K filings; Penmark Research model (n.d. = not in sources used; FY20–23 UHC rounded to $0.1bn).
Source: Company 10-K and 8-K filings (A); Penmark Research model (E).
Growth drivers and cash conversion
Five-year revenue growth of about 12% a year combined premium pricing (6%–7%), MA and Optum volume (4%) and M&A (1%–2%). In 9M FY26A, revenue slowed to 0.6% y/y as UNH shed 0.87m commercial risk lives and 0.83m MA lives y/y (1.27m commercial risk lives since Dec 2024) to restore margins.
Cash conversion stays high, though subsidiary solvency rules trap capital. FCF after SBC converted 77% of adjusted net profit in FY24A ($20bn) and 101% in FY25A ($15bn), while regulated subsidiaries retain about $2.4bn a year.
| Accounting / reserve item | Reported practice & filings evidence | Earnings / cash effect | Status |
|---|---|---|---|
| Medical costs payable | Claims payable stood at $39.4bn at 3Q26 (~47 days of care costs), mainly incurred but not reported (IBNR) reserves. | Short 45–50 day claim tail limits multi-year surprises. | Tracked |
| Non-GAAP exclusions | Excludes intangible amortisation ($1.61bn FY25A), South America sale loss ($8.31bn FY24A) & cyber/restructuring ($2.75bn FY25A). | Gap peaked at +78% in FY24A; narrows to +5% FY27E. | Improving |
| Share-based pay (SBC) | $1,018m FY24A, $971m FY25A, $843m 9M26A; added back in GAAP operating cash flow. | Model deducts SBC as a cash expense in FCF. | Adjusted |
| Segment realignment | FY26 moves Optum Financial from Optum Health into Optum Insight (FY25A OH recast EBIT $1.45bn vs $2.29bn). | Lifts Insight profit; makes raw FY25A/26E margins non-comparable. | Disclosed |
| Goodwill & statutory cash | Goodwill, intangibles and PP&E reach $169.1bn at 3Q26; $86.6bn cash & investments back reserves. | Distorts P/B and EV/EBITDA; we use P/E & FCFE. | Modelled |
Source: SEC FY25 10-K and Q3 FY26 8-K; Penmark Research model.
Revenue accelerates from 0.5% in FY26E to 5% by FY30E as margins rebuild to 7.5%
Source: Penmark Research model.
| Segment build ($bn / %) | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E | Key driver path |
|---|---|---|---|---|---|---|---|
| UHC Medicare & Ret. | 171.3 | 169.3 | 177.8 | 188.4 | 199.7 | 210.7 | −1.2% FY26E; +5.0% FY27E; +6.0% FY28–29E |
| UHC Comm. & State | 94.4 | 95.1 | 96.1 | 98.9 | 102.9 | 107.0 | +1.0% FY27E post-redeterminations; +4.0% LT |
| UHC Employer & Ind. | 79.2 | 80.5 | 82.9 | 86.3 | 90.1 | 94.2 | +3.0% FY27E on >11% trend pricing; +4.5% LT |
| UnitedHealthcare rev. | 344.9 | 344.9 | 356.7 | 373.6 | 392.8 | 411.9 | UHC margin: 3.7% → 4.1% → 4.4% → 4.9% |
| Optum Health rev. | 102.0 | 93.5 | 95.4 | 100.1 | 106.1 | 112.5 | Adj. margin: 3.0% → 4.0% → 5.0% → 6.25% |
| Optum Insight & Rx net | 168.7 | 171.1 | 178.1 | 187.5 | 197.5 | 208.1 | Insight 21.5%–22.0%; Rx 3.85% → 3.80% |
| Corporate eliminations | (168.0) | (159.7) | (165.5) | (174.0) | (183.7) | (194.0) | 35.6%–36.0% of consolidated revenue |
| Consolidated revenue | 447.6 | 449.8 | 464.8 | 487.2 | 512.7 | 538.6 | Adj. EBIT ($bn): 26.7 → 29.5 → 33.2 → 40.5 |
| Adjusted EPS ($) | 16.35 | 20.73 | 23.52 | 27.35 | 31.79 | 36.21 | 15.5% FY27–30E CAGR (inside 13–16% LT) |
Source: Company filings; Penmark Research model. CAGR = compound annual growth rate.
| Line item | Period | Guide / Cons. | Penmark | Reason for gap |
|---|---|---|---|---|
| Adj. EPS ($) | FY26E | ≥20.50 / 20.59 | 20.73 | 9M $18.30; Q4E $2.39 (FY avg. sh) |
| Adj. EPS ($) | FY27E | ≥23.17 / 23.29 | 23.52 | +13.4% y/y (low end 13–16%) |
| MCR (%) | FY26E | 88.3–89.3%* | 87.5% | 9M actual 86.3%; 91.0% Q4E |
| CFO ($bn) | FY26E | ≥18.0* | 27.8 | 9M actual $25.1bn |
| Buybacks ($bn) | FY26E | ~2.5* | 5.03 | 9M actual $5.03bn; $0 Q4E |
| OH margin | FY28E | 6.0–8.0% | 5.0% | Multi-year VBC lag (6% bull) |
Source: Company guidance; clearank.com consensus; Penmark Research model (*Jan 2026 initial guide not updated in 3Q26; full-year EPS uses 904m full-year average shares).
Source: Penmark Research model.
Fixed vs variable cost leverage
Over 85% of UnitedHealth’s cost base is variable medical and pharmacy claims. Operating costs are guided near 12.8% of revenue in FY26, so margin recovery from 4.9% in FY25A to 6.8% in FY28E rests on plan repricing and clinic risk control.
Cash, capex & statutory capital
Capex stays light at 0.85% of revenue ($4.0bn in FY27E), while statutory rules retain $2.4bn to $3.8bn a year. After paying down $3.0bn of debt in FY27E to reach 39.7% debt-to-capital, FCFE rises from $15.6bn to $25.8bn by FY30E.
Peer P/E gives a $266 base value; weighted scenarios give our $298 target
Source: Penmark Research valuation model. Thesis range = base value ($266) ±10%.
| Primary P/E & target build | Basis / formula | Value |
|---|---|---|
| FY27E adjusted EPS | Base model ($20,882m / 888m) | $23.52 |
| Target FY27E P/E multiple | Restated peer median (11.38x) | 11.5x |
| Gross equity value / share | 11.5 × $23.5168 | $270.44 |
| Less: expected RADV PV | 35% × ($10,517m / 902m sh) | ($4.08) |
| Primary base value / share | −23.9% vs $349.91 price | $266.36 |
| Bear (25%) & Bull (25%) | $168.75 (10.5x) / $428.07 (16.0x) | 50% tail |
| Probability-weighted value | 0.25×Bear + 0.50×Base + 0.25×Bull | $282.39 |
| 12m roll-forward factor | 8.18% CoE − 2.72% next-12m div yield | +5.46% |
| 12-month price target | −14.9% price; −12.2% total return | $297.81 |
Source: Penmark Research model.
Source: Penmark Research valuation model.
Why P/E leads and EV, P/B & sum-of-the-parts fail
Managed-care balance sheets distort enterprise and book multiples. EV/EBITDA fails because $86.6bn of cash and investments at 30 Sep 2026 sits partly against $39.4bn of medical costs payable; P/B fails because M&A created over $100bn of goodwill; and $118bn of 9M26 internal billings rules out a sum-of-the-parts valuation.
Why P/E ($266) and DCF ($537) diverge by 102%
Policy risk lives in peer multiples rather than CAPM beta. UNH’s 0.73 Blume beta yields an 8.2% CAPM cost of equity that omits DOJ MA coding probes and MA benchmark rule risk; our base P/E value equates to a 13.0% DCF discount rate.
Matching $350 requires about an 11% discount rate or a 6.4% UHC margin
We cross-check P/E with a 10-year FCFE discounted cash flow (DCF) model through FY35E. We discount equity cash flows at an 8.2% cost of equity rather than a weighted-average cost of capital (WACC, which blends debt and equity costs). Terminal value, at 3.5% growth and an 18% return on new equity, is 66% of gross value. Reverse DCF solves for the single input required to justify the $350 share price.
Source: Penmark Research valuation model.
Source: Penmark Research valuation model.
| Reverse DCF & robustness test | Base | Tested | Val ($/sh) | 12m TR | Rating & takeaway |
|---|---|---|---|---|---|
| Reverse DCF: single input needed to justify $349.91 (other base inputs held) | |||||
| FY27E P/E on $23.52 EPS (incl. RADV) | 11.5x | 15.05x | $349.91 | n.m. | +3.55x premium vs peers |
| FY27E adj. EPS at 11.5x base P/E | $23.52 | $30.78 | $349.91 | n.m. | +30.9% above base EPS |
| UHC FY27E margin at 11.5x P/E | 4.10% | 6.39% | $349.91 | n.m. | +21bp above FY20A peak |
| Cost of equity in FCFE DCF (3.5% g) | 8.18% | 10.70% | $349.91 | n.m. | Base P/E equates to 12.98% DCF rate |
| Model robustness suite (3 of 7 tests change Sell rating → low conviction) | |||||
| 1. As modelled (25 / 50 / 25 weights) | 8.18% | Base | $282.39 | −12.2% | Sell (2.2pp below Hold) |
| 2. Cost of equity −1.0pt (P/E scales) | 8.18% | 7.18% | $337.14 | +3.4% | Flips to Hold |
| 3. Beta at 5Y raw (0.60 vs 0.732) | 0.732 | 0.600 | $309.83 | −4.4% | Flips to Hold |
| 4. Hist. median margin (8.65%) | 6.35% | 8.65% | $374.06 | +15.5% | Flips to Buy (bull risk) |
| 5. Base case alone (100% weight) | 50% wt | 100% wt | $266.36 | −17.0% | Confirms Sell |
| 6. Cost of equity +1.0pt (P/E scales) | 8.18% | 9.18% | $243.15 | −23.3% | Confirms Sell |
| 7. Market beta (1.00 vs 0.732) | 0.732 | 1.000 | $239.51 | −24.3% | Confirms Sell |
Source: Penmark Research model. DOJ coding liability is $0 in the cash bridge as unquantified in filings (carried in our 10.5x bear P/E).
Seven milestones through 2027 test UNH’s 15x multiple
| Date | Event & driver | Penmark expectation | Market / consensus | Likely stock move |
|---|---|---|---|---|
| Dec 2026 | Investor update | Reaffirms ≥$20.50 FY26E & $23.17 FY27E floor. | Street $23.29; bulls seek >$24. | Flat to −4% on floor |
| 19 Jan 2027 | CRUSH comments due | Plans challenge PY2018–27 RADV extrapolation. | 15% drop priced full clawback. | +2%–4% if softened |
| 26 Jan 2027 | 4Q26 & FY27 guide | 4Q26E EPS $2.39, MCR 91.0%; FY27E $23.52. | 4Q ~$2.29; FY27E Street $23.29. | ±5%–8% on MCR |
| Late Jan 27 | 2028 Advance Notice | Modest base lift; chart-review curbs proposed. | Hopes for post-V28 rate relief. | −$1.67/sh if tight |
| 6 Apr 2027 | 2028 MA Final Notice | FY28E M&R +6.0%; MA margin 2%–4%. | Seeks multi-year rate clarity. | Anchors 11.5x P/E |
| Apr 2027 | 1Q27 MCR print | Tests >11% pricing & 4.0% OH. | Smooth step to 6%–8%. | −8%–12% if missed |
| 2H 2027 | 5th Cir. / RADV rule | 35% upheld ($4.08/sh PV); APA appeals run. | Binary headline sensitivity. | +$4 vacated / −$8 full |
Source: CMS regulatory calendar; company releases; Penmark Research model.
Source: CMS calendar; company releases; Penmark Research.
Source: clearank.com (12 Nov 2026); Penmark Research model.
| Indicator | Thesis confirmed (Sell) | Thesis broken (Upgrade) |
|---|---|---|
| Consol. MCR | FY26E ≥87.5% & 1Q27 trend ≥11%. | FY27E EPS >$24.80 (Hold); watch MCR <86.5%. |
| Segment EBIT | FY27E UHC ≤4.2% & OH ≤4.2%. | 8.65% median margin restored (Buy). |
| MA & RADV | 2028 MA notice tight; CRUSH kept. | 5th Cir. vacates RADV & MA rate >4%. |
| DOJ & P/E | DOJ coding probe lingers; P/E 11.5x. | Our base P/E >12.1x (Hold); watch DOJ settlement. |
Source: Penmark Research monitoring framework.
What would change our view: Below about $341 the shares sit in our Hold band; so does a base multiple above 12.1x or FY27E EPS above $24.80, each on its own. A 5.5% UHC margin or a 14x to 16x base multiple also gives Hold; only the historical median margin reaches Buy. UNH closed at $330.48 on 19 Nov, after our pricing date, where our target implies a −7% total return. Under our rating policy (p28), a share price can move outside its band before the rating changes, and we will review the rating under that policy.
Restoring the 8.7% historical median margin (+$108/sh) leads upside risks; unpriced trend (−$41/sh) leads downside
With a low conviction Sell (−12.2% expected total return, 2.2pp inside the Sell band), the main risks to our rating are upside surprises in margins, discount rates or CMS rules. Five bear-case shocks drive downside to $169.
Source: Penmark Research model (modelled per-share value impacts).
| Risk & direction | Odds / weight | Value / sh | Mechanism, filings evidence & thesis impact |
|---|---|---|---|
| Upside: 8.65% historical margin | Robustness | +$107.70 | Restoring the FY20A–FY25A median 8.65% margin lifts value to $374.06 (+15.5% TR, Buy). |
| Upside: Full bull re-rating | 25% bull wt | +$161.71 | Medicaid catch-up (+$18.54), FY27 guide (+$2.61), 5% OH (+$9.91) & 16.0x P/E reach $428.07. |
| Upside: −1pt CoE or 0.60 beta | Macro / Hold | +$27–$55 | 7.18% CoE lifts weighted value to $337.14 (+3.4% TR, Hold); 0.60 beta gives $309.83 (Hold). |
| Upside: RADV rule vacated | Bull (0% RADV) | +$4.08 | 5th Circuit strikes down extrapolation without an FFS adjuster, removing our $4.08/sh deduction. |
| Downside: Trend tops pricing | 20% prob. | −$40.78 | Specialty drugs, outpatient care and Medicaid acuity push UHC margin back to 3.0% in FY27E. |
| Downside: DOJ MA coding probe | 20% prob. | −$23.52 | Civil/criminal MA risk-coding probes curb chart reviews; 1.0x P/E cut to 10.5x costs $23.52/sh. |
| Downside: CRUSH, PBM & MA | 35 / 30 / 40% | −$15.12 | 100% CRUSH (35%, −$7.58), 2028 PBM pass-through (30%, −$5.87) & 2028 MA notice (40%, −$1.67). |
| Key-person, cyber & ESG | Ongoing | In 11.5x P/E | CEO S. Hemsley key-person reliance, Change cyber/restructuring ($2.75bn FY25A) & prior-auth rules. |
Source: SEC FY25 10-K and 2026 DEF 14A; Penmark Research model.
Institutions hold 90% of UNH, and none of 26 analysts rate it Sell
Source: TickerNerd consensus snapshot (10 Nov 2026).
Source: 24/7 Wall St. (18 Nov 2026); clearank.com (12 Nov 2026); Penmark Research.
| Institution (30 Sep 2026 13F) | Sh (m) | % S/O | Val ($bn) | QoQ (m) | QoQ % | 3Q26 activity |
|---|---|---|---|---|---|---|
| 1. The Vanguard Group | 93.21 | 10.40% | 32.61 | −0.31 | −0.3% | Passive / trimmed |
| 2. BlackRock, Inc. | 77.21 | 8.62% | 27.02 | +0.35 | +0.5% | Passive / added |
| 3. State Street Global Adv. | 45.70 | 5.10% | 15.99 | +0.07 | +0.2% | Passive / added |
| 4. FMR LLC (Fidelity) | 31.06 | 3.47% | 10.87 | +3.07 | +11.0% | Largest 3Q buyer |
| 5. Capital World Investors | 28.48 | 3.18% | 9.97 | −1.41 | −4.7% | Reduced Q3 |
| 6. T. Rowe Price Assoc. | 22.18 | 2.48% | 7.76 | −1.66 | −7.0% | Reduced Q3 |
| 7. Geode Capital Mgmt. | 20.75 | 2.32% | 7.26 | −1.01 | −4.6% | Reduced Q3 |
| 8. Charles Schwab Inv. | 20.35 | 2.27% | 7.12 | +0.52 | +2.6% | Added Q3 |
| 9. JPMorgan Chase & Co. | 17.61 | 1.97% | 6.16 | −2.63 | −13.0% | Largest 3Q seller |
| 10. Morgan Stanley | 15.61 | 1.74% | 5.46 | +0.81 | +5.5% | Added Q3 |
| Top 10 institutions | 372.16 | 41.53% | 130.22 | −2.20 | −0.6% | 896.02m basic S/O |
| Total 13F (3,220 filers) | 762.22 | 85.07% | 266.71 | n.d. | n.d. | 13F coverage |
Source: SEC Form 13F filings as of 30 Sep 2026 via Signals (values at 18 Nov $349.91 close; 85.07% 13F coverage vs 89.69% total Yahoo institutional ownership).
| Metric | Reading | As-of / note |
|---|---|---|
| Market cap (18 Nov dil.) | $315.6bn | 902m sh at $349.91 ($313.5bn basic) |
| 3M avg. daily volume | 5.49m sh (~$1.9bn) | Yahoo Finance (to 18 Nov) |
| CRUSH 2-day volume | 8.04m / 17.39m sh | 17 & 18 Nov 26 |
| Short int. / % float | 13.96m / 1.74% | 30 Oct (2.41d to cover) |
| Inst. / insider % | 89.69% / 0.19% | Yahoo / 2026 Proxy |
| 50d / 200d MA | $390.64 / $367.91 | 18 Nov (below both MAs) |
| Current div. rate | $9.28/sh (2.65%) | Current rate; ex 7 Dec, pay 15 Dec |
Source: Yahoo Finance through 18 Nov 2026 (current annualised dividend rate $9.28/sh vs $9.51/sh expected next 12 months).
Positioning and trading profile
Street ratings stay overwhelmingly bullish despite mixed 3Q26 13F flows. Across 26 analysts (10 Nov 2026), 21 rate UNH Buy and none rate it Sell; non-contemporaneous targets span $380 to $531 (median $490 on 12 Nov; mean $476 on 18 Nov), sitting $82 to $233 above our $298 target.
Short interest stood at 1.74% of float (13.96m shares, 2.41 days to cover) on 30 October 2026. During the 17–18 Nov CRUSH sell-off, volume rose to 17.39m shares (3.2x average), leaving UNH below its 50-day ($391) and 200-day ($368) moving averages.
Linked annual financial model (FY25A–FY30E) and nine-quarter operating progression
| US$m / per share | FY25A | 9M26A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 447,567 | 336,447 | 449,847 | 464,769 | 487,209 | 512,700 | 538,566 |
| Adj. operating earnings | 21,716 | 23,208 | 26,728 | 29,500 | 33,190 | 37,053 | 40,502 |
| GAAP operating earnings | 18,964 | 23,544 | 27,064 | 29,500 | 33,190 | 37,053 | 40,502 |
| Interest & disposal loss | (4,267) | (3,089) | (4,054) | (3,823) | (3,850) | (3,957) | (4,064) |
| Tax & NCI | (2,641) | (4,581) | (5,274) | (5,838) | (6,731) | (7,583) | (8,341) |
| GAAP net earnings | 12,056 | 15,874 | 17,736 | 19,839 | 22,609 | 25,513 | 28,098 |
| Adjusted net earnings | 14,897 | 16,598 | 18,743 | 20,882 | 23,597 | 26,453 | 28,990 |
| Adjusted EPS ($) | 16.35 | 18.30 | 20.73 | 23.52 | 27.35 | 31.79 | 36.21 |
| GAAP diluted EPS ($) | 13.23 | 17.50 | 19.62 | 22.34 | 26.20 | 30.66 | 35.09 |
| Diluted avg. shares (m) | 911 | 906 | 904 | 888 | 863 | 832 | 801 |
| Cash flow & FCFE build (forecast treats SBC as cash cost) | |||||||
| Operating cash flow | 19,697 | 25,087 | 27,847 | 24,917 | 28,128 | 31,394 | 34,208 |
| Capital expenditure | (3,622) | (2,421) | (3,801) | (3,951) | (4,141) | (4,358) | (4,578) |
| FCF after SBC | 15,104 | 21,823 | 23,203 | 20,966 | 23,986 | 27,036 | 29,630 |
| FCFE (after reg. capital) | n.a. | n.a. | n.a. | 15,550 | 21,001 | 23,544 | 25,801 |
| Dividends paid | 7,916 | 6,170 | 8,253 | 8,542 | 8,769 | 8,889 | 8,990 |
| Share repurchases | 5,545 | 5,031 | 5,031 | 7,008 | 12,233 | 14,654 | 16,811 |
| Balance sheet & key ratios (period-end; 9M26A = 30 Sep 2026) | |||||||
| Cash & investments | 82,372 | 86,613 | 85,909 | 88,290 | 91,275 | 94,768 | 98,597 |
| Total assets | 309,581 | 312,782 | 312,528 | 315,131 | 318,661 | 322,813 | 327,294 |
| Medical costs payable | 39,337 | 39,352 | 39,320 | 40,669 | 42,591 | 44,774 | 46,958 |
| Total debt | 78,389 | 74,331 | 74,331 | 71,295 | 71,295 | 71,295 | 71,295 |
| Shareholders’ equity | 100,090 | 104,129 | 103,907 | 108,197 | 109,804 | 111,774 | 114,071 |
| Adjusted ROE (%) | 15.0% | n.m. | 18.4% | 19.7% | 21.6% | 23.9% | 25.7% |
Source: SEC filings; Penmark Research model (debt/capital: 43.9% FY25A, 41.7% FY26E, 39.7% FY27E, 38.5% FY30E).
| Quarterly | 4Q24A | 1Q25A | 2Q25A | 3Q25A | 4Q25A | 1Q26A | 2Q26A | 3Q26A | 4Q26E |
|---|---|---|---|---|---|---|---|---|---|
| Revenue ($bn) | 100.8 | 109.6 | 111.6 | 113.2 | 113.2 | 111.7 | 112.1 | 112.7 | 113.4 |
| GAAP EBIT ($bn) | 7.77 | 9.10 | 5.17* | 4.32 | 0.38 | 9.00 | 8.00 | 6.56 | 3.52 |
| Adj. EPS ($) | 6.81 | 7.20 | 4.08 | 2.92 | 2.11 | 7.23 | 6.38 | 4.69 | 2.39 |
| MCR (%) | 87.6% | 84.8% | 89.4% | 89.9% | 92.4% | 83.9% | n.a. | 88.4% | 91.0% |
Source: SEC filings; Penmark Research model (*2Q25 implied from 9M25 $18.58bn less 1Q & 3Q; 2Q26 MCR not in model).
| Segment EBIT ($m) & KPIs | FY24A | FY25A | 9M26A | FY26E | FY27E | FY28E | FY30E |
|---|---|---|---|---|---|---|---|
| UnitedHealthcare adj. EBIT | 16,248 | 9,578 | 12,326 | 12,876 | 14,626 | 16,439 | 20,183 |
| Optum Health adj. EBIT | 7,930 | 2,286* | 3,074 | 2,824 | 3,814 | 5,006 | 7,032 |
| Optum Insight adj. EBIT | 4,393 | 3,727* | 3,416 | 4,756 | 4,843 | 5,302 | 6,184 |
| Optum Rx adj. EBIT | 5,836 | 6,125 | 4,392 | 6,272 | 6,216 | 6,442 | 7,103 |
| MA / Medicaid / Comm. risk (m) | 7.8 / 7.4 / 8.8 | 8.4 / 7.4 / 8.2 | 7.6 / 6.7 / 7.6 | n.d. | n.d. | n.d. | n.d. |
Source: SEC filings; Penmark Research model (*FY25A pre-recast; recast OH $1,449m, Insight $4,564m).
Non-GAAP reconciliation, glossary, ratio definitions, peer rules and source cut-offs
| US$m / per share | FY24A | FY25A | 9M26A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|---|
| GAAP net earnings to UNH | 14,405 | 12,056 | 15,874 | 17,736 | 19,839 | 22,609 |
| Plus: intangible amort. (pre-tax) | 1,665 | 1,613 | 1,053 | 1,405 | 1,300 | 1,235 |
| Plus: tax, cyber & disposal items | 9,629 | 1,228 | (329) | (398) | (257) | (247) |
| Adjusted net earnings | 25,699 | 14,897 | 16,598 | 18,743 | 20,882 | 23,597 |
| GAAP diluted EPS ($) | 15.51 | 13.23 | 17.50 | 19.62 | 22.34 | 26.20 |
| Adjusted EPS ($) | 27.66 | 16.35 | 18.30 | 20.73 | 23.52 | 27.35 |
Source: UNH Q4 FY25 and Q3 FY26 8-K reconciliations; Penmark Research model.
Glossary
- MCR: Medical costs divided by premium revenue.
- MA & V28: Medicare Advantage plans and CMS’s 2024–26 V28 risk-model phase-in.
- RADV & CRUSH: Risk-coding audits and CMS-6098-P extrapolating PY2018–27 errors.
- VBC & FFS: Capitated value-based care vs traditional fee-for-service billing.
- PBM & ASO: Pharmacy benefit manager (Optum Rx) and employer fee-only administration.
- IBNR: Medical costs incurred by members but not yet reported in claims payable.
Methodology & data cut-offs
We model UNH as an integrated US health insurer and health-services group facing heavy federal regulation and policy risk. Valuation is dated 20 Nov 2026 and priced at the 18 Nov 2026 NYSE close of US$349.91 (US$ issuer; no FX or ADR adjustments). Limits: FY25A Optum segments are pre-recast; FY27E revenue consensus was not found; DOJ liability is $0 in the cash bridge.
Sources: Penmark Research model (20 Nov 2026); SEC 10-K, 10-Q, 8-K, DEF 14A, 13F & Form 4 filings; Yahoo Finance market data (18 Nov 2026); CMS, KFF and Drug Channels statistics.
| Measure | Definition in Penmark model | Basis |
|---|---|---|
| Adjusted EPS | GAAP diluted EPS plus after-tax intangible amortisation and non-operating items. | Non-GAAP 8-K |
| FCF after SBC | Operating cash flow less capital expenditure less share-based compensation. | Cash flow |
| FCFE | FCF after SBC less statutory capital retained in subsidiaries plus target debt reset. | Equity DCF |
| Adjusted ROE | Adjusted net earnings divided by average equity (peer fwd ROE = FY27E EPS / FY25 BVPS). | Return ratio |
| Restated peer P/E | Peer FY27E P/E × (UNH g / Peer g) × ((1 − 3.5% / UNH ROE) / (1 − 3.5% / Peer ROE)). | Peer formula |
Source: Company filings; Penmark Research model.
| Peer (ticker) | Business model & inclusion rule | Raw P/E | FY27E g | Restated |
|---|---|---|---|---|
| Elevance (ELV) | Commercial/Medicaid/MA insurer + Carelon services; included (≤25% growth rule). | 13.39x | 12.0% | 15.89x (Bull) |
| Cigna Group (CI) | Commercial ASO health plan + Evernorth (Express Scripts PBM); included. | 8.65x | 10.0% | 11.38x (Base) |
| CVS Health (CVS) | Aetna insurer + Caremark PBM + Oak Street clinics + retail; included. | 9.40x | 13.1% | 10.40x (Bear) |
| CNC / MOH / HUM | Excluded: CNC lacks 2027 growth guide (18.42x sens.); MOH (+81%) & HUM (+93%) rebound. | 13.0–21.8x | 10.6–93% | Excluded |
Source: Company outlooks; Penmark Research model as of 18 Nov 2026.
Analyst certification and important disclosures
Ratings
Ratings are based on the total return from the share price to our 12-month price target, including dividends. The price target is weighted across bull, base and bear scenarios.
| Buy | Total return to price target above +10% |
| Hold | Total return to price target from −10% to +10%, inclusive |
| Sell | Total return to price target below −10% |
We review ratings at each set of results and whenever the facts change materially. A share price can move outside its band before the rating changes, and targets may not be reached.
Analyst certification
The Penmark Team certifies that (1) the views in this report accurately reflect its views about the subject company and its securities, and (2) no part of its compensation was, is or will be directly or indirectly related to the specific ratings, price targets or views in this report.
Contact
Penmark Research
Questions about our research:
research@penmarkresearch.com
All our research and coverage:
penmarkresearch.com
Basis of preparation
This report uses information publicly available up to its publication date. Share prices are closing prices on the trading day before the publication date, unless stated otherwise. Forecasts, valuations and price targets are Penmark Research’s own, and forecast periods are marked E. Sources are shown beneath each exhibit.
Valuation and price targets
Price targets are based on the valuation methods set out in each report and are weighted across bull, base and bear scenarios. The main risks to each rating and price target are described in the report. Penmark Research updates its coverage after each set of results but is not obliged to update a report at any other time.
Independence and conflicts of interest
Penmark Research is independent. It does not provide investment banking, brokerage, market-making or asset management services, does not trade securities, and does not accept payment from any company for research coverage. Companies do not see or review Penmark Research reports before publication.
No member of the Penmark Team holds a long or short position, directly or through derivatives, in the securities of any company Penmark Research covers.
Regulatory status
Penmark Research publishes general, impersonal investment research on a regular basis. It is not registered as an investment adviser with the US Securities and Exchange Commission or any state securities authority, is not a registered broker-dealer and is not a member of FINRA. Penmark Research does not give advice tailored to any person’s circumstances.
Not investment advice or an offer
This report is for information only. It is not personalised investment advice and is not an offer or solicitation to buy or sell any security or other financial instrument. It does not take into account any reader’s objectives, financial situation or needs. Readers should make their own investment decisions and seek independent professional advice where appropriate.
Forward-looking statements and risk
Forecasts, valuations and price targets are estimates based on assumptions that may prove wrong, and they may not be achieved. Opinions are current as of the publication date and may change without notice. Investing in equities involves risk, including the loss of capital. Share prices can be volatile, and past performance is not a reliable indicator of future results.
Data and sources
Company financials, operating data and filings come from company filings, earnings releases and earnings calls. Market data and any consensus estimates come from third-party sources named beneath the relevant exhibit; consensus figures from aggregators are unofficial. Penmark Research does not use other brokers’ research. Third-party data belong to their providers and may not be extracted from this report.
Accuracy and liability
Information is taken from sources believed to be reliable, but Penmark Research makes no representation or warranty as to its accuracy, completeness or timeliness. To the fullest extent permitted by law, Penmark Research accepts no liability for any loss arising from use of this report. Descriptions of litigation and regulatory matters reflect allegations and public records, not findings, unless stated. If a published report is corrected, the corrected version carries an “Updated” date at penmarkresearch.com.
Distribution and access
Penmark Research reports are available to registered users of penmarkresearch.com. Downloads and programmatic access are governed by the Penmark Research subscription terms. This report is not directed at, or intended for, any person in Singapore or India, and access from those countries is blocked. It is not intended for distribution to, or use by, any person in any jurisdiction where that would be contrary to law or regulation or would subject Penmark Research to registration or licensing requirements there.
Copyright and permitted use
© Penmark Research. All rights reserved. Penmark Research is a trade name of Brightriver Labs. Readers may share a link to this report but may not copy, reproduce, redistribute, sell or use its content, including for text and data mining, without written consent. Contact: research@penmarkresearch.com.